Last reviewed · How we verify
NCT04731844
Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer
Phase 2 trial testing Curcumin plus Piperine in Prostate Cancer in 40 participants. Currently enrolling.
31 May 2025
Quick facts
| Lead sponsor | University of Rochester |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 14 December 2021 |
| Primary completion | 31 May 2025 |
| Estimated completion | 31 May 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Curcumin plus Piperine — full drug profile →
Conditions studied
- Prostate Cancer — all drugs for Prostate Cancer →
- Multiple Myeloma — all drugs for Multiple Myeloma →
- Smoldering Multiple Myeloma (SMM) — all drugs for Smoldering Multiple Myeloma (SMM) →
- Monoclonal Gammopathy of Undetermined Significance — all drugs for Monoclonal Gammopathy of Undetermined Significance →
Sponsor
University of Rochester
Who can join
18 and older, any sex, with Prostate Cancer or Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To explore the use of curcumin and piperine supplementation at a dose of 4 gram/5mg twice a day in early stage prostate cancer patient undergoing active surveillance or patients on observation for MGUS/ low-risk smoldering myeloma.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Topoisomerase II Poisons: Converting Essential Enzymes into Molecular Scissors.
Vann KR, Oviatt AA, Osheroff N. · · 2021 · cited 67× · PMID 34008964 · DOI 10.1021/acs.biochem.1c00240 -
Heat shock protein 90: biological functions, diseases, and therapeutic targets.
Wei H, Zhang Y, Jia Y, Chen X, et al · · 2024 · cited 54× · PMID 38283176 · DOI 10.1002/mco2.470 -
Post-translational protein lactylation modification in health and diseases: a double-edged sword.
Gong H, Zhong H, Cheng L, Li LP, et al · · 2024 · cited 42× · PMID 38200523 · DOI 10.1186/s12967-023-04842-9 -
Oxidative Stress Inducers in Cancer Therapy: Preclinical and Clinical Evidence.
Nizami ZN, Aburawi HE, Semlali A, Muhammad K, et al · · 2023 · cited 40× · PMID 37371889 · DOI 10.3390/antiox12061159 -
Lactylation in health and disease: physiological or pathological?
Zhao L, Qi H, Lv H, Liu W, et al · · 2025 · cited 36× · PMID 39897556 · DOI 10.7150/thno.105353 -
Role of Plant-Derived Active Constituents in Cancer Treatment and Their Mechanisms of Action.
Khan AW, Farooq M, Haseeb M, Choi S. · · 2022 · cited 31× · PMID 35456005 · DOI 10.3390/cells11081326 -
Lactylation: A Novel Post-Translational Modification with Clinical Implications in CNS Diseases.
Liu J, Zhao F, Qu Y. · · 2024 · cited 25× · PMID 39334941 · DOI 10.3390/biom14091175 -
Applications of Curcumin and Its Nanoforms in the Treatment of Cancer.
Mundekkad D, Cho WC. · · 2023 · cited 23× · PMID 37765192 · DOI 10.3390/pharmaceutics15092223
Verify or expand the search:
- PubMed search for NCT04731844
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Curcumin plus Piperine
Trials testing the same drug.
- NCT07149961 — Curcumin-Piperine Supplementation in STEMI - SPICE STEMI Trial · NA · completed
Other recruiting trials for Prostate Cancer
Currently open trials in the same condition.
- NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
- NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
- NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
- NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
- NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting
Other University of Rochester trials
Trials by the same sponsor.
- NCT07075965 — Calcium Channel Blocker in Myotonic Dystrophy Type 1 · Phase 1 · not yet recruiting
- NCT07423104 — A Study of Cladribine, Low Dose Cytarabine, and Venetoclax in Treatment of Relapsed/Refractory or Secondary Acute Myeloi · Phase 2 · not yet recruiting
- NCT05744869 — SBAT for Health Equity · NA · not yet recruiting
- NCT06052956 — Efficacy of Methylene Blue Photodynamic Therapy for Treatment of Deep Tissue Abscesses · Phase 2 · not yet recruiting
- NCT07032636 — Reducing Crises and Suicide Within the Idaho Army National Guard · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04731844 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Rochester
- Last refreshed: 12 July 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04731844.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing